A double-blind, randomised, placebo-controlled, first in human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics of oral KLH-2109 and the effect of food in Caucasian and Japanese healthy female post- and pre-menopausal subjects after single and multiple ascending oral doses

Trial Profile

A double-blind, randomised, placebo-controlled, first in human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics of oral KLH-2109 and the effect of food in Caucasian and Japanese healthy female post- and pre-menopausal subjects after single and multiple ascending oral doses

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs KLH 2109 (Primary)
  • Indications Endometriosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Kissei Pharmaceutical
  • Most Recent Events

    • 07 Jun 2017 Results published in an ObsEva SA media release.
    • 07 Jun 2017 According to an ObsEva SA media release, status changed from recruiting to completed.
    • 07 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top